View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
March 27, 2020

VERO Biotech’s Genosyl secures FDA emergency use access

Biotechnology firm VERO Biotech has received expanded access emergency use from the US Food and Drug Administration (FDA) for its Genosyl DS to treat cardiopulmonary symptoms caused by Covid-19.

Previously, the FDA approved Genosyl, inhaled nitric oxide (iNO), for treating persistent pulmonary hypertension of the newborn (PPHN).

Genosyl DS is an iNO delivery system expected to aid during the short supply of hospital beds and ventilators.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology